Longevity Biotech Startup Funding
In our updated market reports, you will find everything you need
SUMMARY
This report analyzes disclosed equity financings raised by pure-play longevity biotech companies between August 2024 and July 2026, a 24-month window covering companies developing therapeutics and diagnostics aimed at slowing or reversing biological aging. We only kept rounds of $300K or more, excluded debt, grants, undisclosed rounds, and broader preventive-health or non-longevity biotech companies, and ended with 16 disclosed deals across 13 unique companies.
Over this period, the longevity biotech market raised $2.18B in disclosed equity funding. The market looks large on dollars, but the company base remains small.
Funding in the longevity biotech market is highly concentrated. The top deal alone represents 45.9% of all disclosed capital, while the top 3 deals represent 75.0%.
The market is shaped by a few very large platform bets. Excluding rounds above $50M reduces total capital from $2.18B to $235.7M.
Deal flow is modest rather than broad. The dataset averages 0.70 disclosed deals per month, with a median of 1 deal per month.
The median round size is $35M, while the average round size is $136.2M. That gap shows how strongly the average is pulled upward by Retro Biosciences and NewLimit.
Cell Rejuvenation Platforms lead by capital, with $1.02B raised. Epigenetic Reprogramming leads by deal count, with 5 disclosed rounds.
North America dominates the longevity biotech market. It accounts for 14 of 16 deals and 98.7% of disclosed capital raised.
Early-stage rounds account for 61.0% of capital, but this is misleading. Retro Biosciences’ $1B Series A makes early-stage funding look much larger than normal.
Repeat investor participation is one of the strongest credibility signals. Kleiner Perkins, Eli Lilly, Founders Fund, Human Capital, Dimension, and Mubadala appear more than once.
What are all the funding deals in the longevity biotech market from August 2024 to July 2026?
The table below lists every disclosed equity round raised by pure-play longevity biotech companies between August 2024 and July 2026. We count as pure-play longevity biotech companies those focused on therapeutics and diagnostics aimed at slowing or reversing biological aging.
Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors | Source |
|---|---|---|---|---|---|---|---|---|
| BioAge Labs | Develops metabolic-disease therapies by targeting human aging biology | Longevity Therapeutics | Sep 2024 | Unknown | $198M | North America | Public investors | BioSpace |
| Shift Bioscience | Uses AI to identify safe cell-rejuvenation gene programs | Epigenetic Reprogramming | Oct 2024 | Seed | $16M | Europe | Not disclosed | Shift Bioscience |
| HERVolution Therapeutics | Develops dark-genome immunotherapies for aging-related diseases | Longevity Therapeutics | Dec 2024 | Series A | $11.7M | Europe | Not disclosed | HERVolution Therapeutics |
| Retro Biosciences | Develops autophagy, plasma, and cellular reprogramming longevity therapies | Cell Rejuvenation Platforms | Jan 2025 | Series A | $1,000M | North America | Not disclosed | Financial Times |
| Loyal | Develops FDA-regulated lifespan-extension drugs for dogs | Longevity Therapeutics | Feb 2025 | Series B | $22M | North America | Not disclosed | Business Wire |
| NewLimit | Develops epigenetic reprogramming medicines for age-related disease | Epigenetic Reprogramming | May 2025 | Series B | $130M | North America | Founders Fund; Kleiner Perkins; Dimension; Human Capital | TechCrunch |
| OneSkin | Develops senescence-targeting peptide products for skin longevity | Senolytic Drug Developers | Aug 2025 | Series A | $20M | North America | Prelude Growth Partners | PR Newswire |
| NewLimit | Develops epigenetic reprogramming medicines for age-related disease | Epigenetic Reprogramming | Oct 2025 | Series B | $45M | North America | Kleiner Perkins; Eli Lilly; Human Capital; Dimension | MarketScreener |
| Generation Lab | Builds biological-age diagnostics and organ aging tests | Age Biomarker Companies | Oct 2025 | Seed | $11M | North America | Not disclosed | Generation Lab |
| Junevity | Develops siRNA cell-reprogramming therapies for metabolic aging | Cell Rejuvenation Platforms | Nov 2025 | Seed | $20M | North America | Not disclosed | Junevity |
| Juvena Therapeutics | Develops AI-enabled regenerative biologics restoring tissue function | Regenerative Longevity Therapies | Jan 2026 | Series B | $33.5M | North America | Bison Ventures; Eli Lilly Ventures; Mubadala Capital; Manta Ray | Business Wire |
| L-Nutra | Develops clinical nutrition therapies for longevity and disease remission | Longevity Clinical Trials | Jan 2026 | Series D+ | $36.5M | North America | Mubadala | PR Newswire |
| Loyal | Develops FDA-regulated lifespan-extension drugs for dogs | Longevity Therapeutics | Feb 2026 | Series C | $100M | North America | age1 | Business Wire |
| Life Biosciences | Develops partial epigenetic reprogramming therapies for diseases of aging | Epigenetic Reprogramming | Apr 2026 | Series D+ | $80M | North America | Not disclosed | Life Biosciences |
| NewLimit | Develops epigenetic reprogramming medicines for age-related disease | Epigenetic Reprogramming | Jun 2026 | Series C | $435M | North America | Kleiner Perkins; Founders Fund; Eli Lilly; Dimension; Human Capital | STAT |
| Rapalogix Health | Develops longevity-based skin-health products targeting skin aging biology | Regenerative Longevity Therapies | Jun 2026 | Series A | $20M | North America | Not disclosed | Rapalogix Health |
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this longevity biotech funding tracker by reviewing every publicly disclosed equity round raised by pure-play longevity biotech companies between August 2024 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to therapeutics, diagnostics, rejuvenation platforms, senolytics, biological-age biomarkers, or regenerative approaches aimed at slowing or reversing biological aging.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt, credit lines, and acquisitions without primary equity financing are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play longevity biotech companies. And fourth, every entry had to be confirmed by a direct company announcement, a press release, or a tier-1 media report, with the source URL preserved for every row.
The final dataset contains 16 disclosed deals across 13 unique companies, and every average, median, share, and concentration ratio is computed on that disclosed sample. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only longevity biotech funding tracker.
How active has fundraising been in the longevity biotech market?
As of July 2026, fundraising in the longevity biotech market has been active in dollars but limited in deal count. Over the past 24 months, pure-play longevity biotech companies raised 16 disclosed equity rounds and $2.18B combined.
That works out to only 0.70 disclosed deals per month. The median month had 1 deal, so the longevity biotech market is visible, but not broad.
The dollar total also needs careful interpretation. Average capital raised per month was $94.7M, but that number is heavily pulled up by Retro Biosciences’ $1B Series A.
Outside the biggest rounds, activity looks much smaller. Excluding rounds above $50M reduces total disclosed capital to $235.7M, which shows that normal financing depth remains thin.
How concentrated has fundraising been in the longevity biotech market?
As of July 2026, fundraising in the longevity biotech market has been extremely concentrated. Over the past 24 months, the top deal alone accounted for 45.9% of all disclosed capital raised.
The top 3 deals represented 75.0% of total capital, while the top 5 reached 85.5%. This means the headline market total is mostly a story about a few very large rounds.
Retro Biosciences is the main concentration driver. Its $1B Series A is larger than every other category except Epigenetic Reprogramming and larger than all non-megaround capital combined.
The top 10 deals accounted for 95.5% of disclosed capital. That leaves very little capital spread across the smaller companies in the longevity biotech market.
How much of the longevity biotech funding signal is driven by outliers?
As of July 2026, the funding signal in the longevity biotech market is strongly driven by outliers. Over the past 24 months, 6 of 16 disclosed deals were above $50M, and 4 were above $100M.
Those 6 rounds above $50M represented 37.5% of deal count but the large majority of capital raised. Removing them cuts the market from $2.18B to only $235.7M.
The average round size was $136.2M, while the median round size was $35M. The median is a better guide to normal financing conditions because the average is distorted by a small number of large checks.
This outlier dependency matters for interpretation. The longevity biotech market looks mature by capital raised, but the underlying distribution still looks narrow and fragile.
Is the longevity biotech market broad with many targets, or narrow with few fundable companies?
As of July 2026, the longevity biotech market is narrow rather than broad. Over the past 24 months, only 13 unique companies produced 16 disclosed equity rounds.
The small company count matters because it limits the investable universe. A few companies, especially NewLimit and Loyal, account for repeated financings inside the same period.
NewLimit is the clearest progression story in the dataset. It raised $130M, then $45M, then $435M in roughly thirteen months, which suggests repeat technical and investor validation.
The market also shows few first financings. Most companies raising in the period were already known entities, which means capital is recycling into established longevity bets rather than constantly forming new ones.
Is longevity biotech mostly an early-stage formation market or a late-stage scaling market?
As of July 2026, the longevity biotech market looks early-stage by stage label, but not by capital behavior. Over the past 24 months, Seed, Series A, and Series B rounds represented 61.0% of disclosed capital.
That early-stage share is misleading because Retro Biosciences’ $1B Series A dominates the category. Series A alone represented 48.3% of total capital, but the median Series A was only $20M.
Late-stage capital was still meaningful. Series C, Series D+, Growth Equity, and Unknown rounds represented $849.5M, or 39.0% of disclosed capital.
Seed activity remained modest. The 3 Seed rounds raised only $47M combined, which suggests company formation continues but investor conviction concentrates after platform plausibility improves.
Which categories attract the most investor attention in longevity biotech?
As of July 2026, Epigenetic Reprogramming attracted the most investor attention in the longevity biotech market by deal count. Over the past 24 months, it produced 5 of 16 disclosed deals, or 31.3% of activity.
Longevity Therapeutics followed with 4 deals, representing 25.0% of disclosed activity. That category includes BioAge Labs, HERVolution Therapeutics, and Loyal’s two rounds.
By capital raised, Cell Rejuvenation Platforms led the longevity biotech market with $1.02B, or 46.8% of total disclosed capital. But that category’s lead is almost entirely driven by Retro Biosciences.
Epigenetic Reprogramming is the more repeatable category signal. It raised $706M across 5 deals, combining NewLimit, Shift Bioscience, and Life Biosciences into a broader funding pattern.
Which categories attract disproportionately large checks in the longevity biotech market?
As of July 2026, Cell Rejuvenation Platforms attracted the most disproportionately large checks in the longevity biotech market. Over the past 24 months, the category had only 2 deals but captured 46.8% of total capital.
Its capital-share-to-deal-share ratio was 3.75, the highest in the dataset. That makes the category look dominant by dollars, but the signal is heavily dependent on Retro Biosciences.
Epigenetic Reprogramming was more balanced. It represented 31.3% of deals and 32.4% of capital, giving it a capital-share-to-deal-share ratio of 1.04.
Other categories attracted smaller checks relative to their visibility. Age Biomarker Companies had 6.3% of deals but only 0.5% of capital, suggesting diagnostics remain enabling infrastructure rather than the main value-capture layer.
Which geographies matter most for fundraising in the longevity biotech market?
As of July 2026, North America mattered overwhelmingly most for fundraising in the longevity biotech market. Over the past 24 months, it captured $2.15B, or 98.7% of disclosed capital.
North America also led on deal count. It produced 14 of 16 disclosed rounds, or 87.5% of activity, with an average round size of $153.6M.
Europe had only 2 disclosed deals and $27.7M raised. Its median round size was $13.85M, far below North America’s $40.75M median.
Asia-Pacific, Latin America, the Middle East, and Africa had no qualifying disclosed equity rounds in this dataset. That does not mean no scientific work exists there, but it does mean public pure-play financing was absent.
Is the longevity biotech opportunity set broad or concentrated in one hub?
As of July 2026, the longevity biotech opportunity set is concentrated in one dominant financing hub. Over the past 24 months, North America accounted for nearly all disclosed capital and most disclosed deals.
This concentration is stronger by dollars than by deals. North America had 87.5% of deal count but 98.7% of capital, which means its rounds were much larger than Europe’s.
Europe appears as a source of scientific startups, but not as a comparable scale-up financing environment. Shift Bioscience and HERVolution Therapeutics are visible, but their combined capital remains small.
The geographic pattern suggests longevity biotech financing is still tied to U.S. capital markets, U.S. biotech investors, and U.S.-style platform financing. The market is global in science, but not yet global in large funding rounds.
Is longevity biotech a market of small experiments or scaled financings?
As of July 2026, the longevity biotech market is a mix of small experiments and scaled financings, but the dollar signal is dominated by scaled rounds. Over the past 24 months, 6 of 16 deals were $50M or larger.
The size distribution is barbell-shaped. There were no rounds under $5M, 6 rounds between $5M and $20M, 4 rounds between $20M and $50M, and 6 rounds above $50M.
This means the market has early translational activity, but not a dense middle. Many companies are either raising modest specialist rounds or very large platform financings.
The median round size of $35M gives a better picture of normal conditions than the $136.2M average. The average is mainly a reflection of Retro Biosciences, NewLimit, BioAge Labs, and Loyal.
Who are the investors that appear the most in longevity biotech fundraising?
As of July 2026, only a small group of investors appeared more than once in longevity biotech fundraising. Over the past 24 months, the repeat names were concentrated around NewLimit, Juvena Therapeutics, and L-Nutra.
Kleiner Perkins appeared in 3 deals, all tied to NewLimit. Eli Lilly or Eli Lilly Ventures also appeared in 3 deals, across NewLimit, Juvena Therapeutics, and NewLimit again.
Founders Fund, Human Capital, and Dimension each appeared in 2 disclosed NewLimit financings. That repeat support makes NewLimit the clearest investor-conviction story in the longevity biotech market.
Mubadala appeared across Juvena Therapeutics and L-Nutra, while Manta Ray was cited around Juvena’s prior backing and Series B participation. These repeat appearances matter because round announcements rarely disclose exact investor check sizes.
The key reading rule is simple. In longevity biotech, repeated access to the same high-quality investors is more meaningful than one isolated large round.
INSIGHTS
The insights below come from reviewing every disclosed equity round in the longevity biotech market between August 2024 and July 2026. They are not row-by-row summaries. They are the reusable patterns that kept showing up across the 16-deal dataset, and they are meant to stay useful when reading any future longevity biotech funding announcement.
- The longevity biotech market is not broadly liquid. It is barbell-shaped, with a few very large rounds and a small group of modest early rounds. The missing middle matters because it suggests the market has not yet developed a deep financing ladder.
- Retro Biosciences alone changes the interpretation of the whole market. Its $1B Series A represents 45.9% of disclosed capital. Any top-line statement about longevity biotech funding during this period is partly a statement about one exceptional financing.
- The top 3 deals represent 75.0% of disclosed capital. That makes market size a weak proxy for broad validation. A better question is whether many independent companies can raise, not whether one or two companies can raise a lot.
- Excluding rounds above $50M reduces total capital from $2.18B to $235.7M. This shows how small the investable base becomes beneath the headline financings. The market is more fragile than the aggregate dollar number suggests.
- Epigenetic Reprogramming is the most repeatable category signal. It has the most deals and still keeps a capital-share-to-deal-share ratio above 1.0. That combination suggests investor interest is broader than one company.
- Cell Rejuvenation Platforms have the highest capital efficiency ratio, but the signal is not yet broad. The category looks dominant by dollars because of Retro Biosciences. It does not yet look dominant by company count.
- NewLimit is the clearest progression story in the dataset. It raised $130M, then $45M, then $435M inside roughly thirteen months. That pattern suggests investors rewarded staged technical de-risking rather than only founder narrative.
- Repeat blue-chip investor participation is a stronger signal than round size alone. NewLimit’s repeated support from Kleiner Perkins, Founders Fund, Human Capital, Dimension, and Eli Lilly is more meaningful than a single isolated announcement.
- Longevity therapeutics outside reprogramming are relevant but less capital-dense. They account for 25.0% of deals but only 15.2% of capital. Investors are interested, but less willing to assign extreme platform-scale outcomes.
- Loyal shows why regulatory proximity matters. Its two rounds total $122M because canine lifespan-extension drugs have a clearer FDA path than broad human anti-aging claims. Concrete regulatory milestones make the longevity story more financeable.
- The canine route is a credibility shortcut for longevity drug development. Loyal’s funding is tied to FDA technical milestones, which makes it one of the few longevity cases where capital follows a concrete regulatory proof point.
- Biological-age diagnostics are underfunded relative to their visibility in the longevity narrative. Generation Lab raised only $11M. Investors appear to see biomarkers as enabling infrastructure rather than the main value-capture layer.
- Clinical nutrition has validation, but weaker venture leverage than programmable biology. L-Nutra’s $36.5M round is meaningful, but far below therapeutic and reprogramming platform rounds. The market rewards prescription-like upside more than wellness-adjacent positioning.
- The strongest funding signal is aging biology tied to a recognized disease indication. NewLimit targets liver disease, Life Biosciences targets optic neuropathies, BioAge targets metabolic disease, and Loyal targets canine lifespan extension.
- Companies that translate aging biology into near-term indications raise more credibly than companies selling generalized lifespan extension. This should be a screening rule for future longevity biotech financings.
- The market funds aging as a platform thesis but regulates it as disease-specific medicine. Investors like rejuvenation narratives, but companies still need liver, optic, metabolic, skin, or veterinary indications to move forward.
- Strategic pharma participation is still selective rather than widespread. Eli Lilly appears repeatedly, but many other major pharma names are absent. Longevity biotech is promising, but not yet fully validated as a pharma category.
- Large rounds cluster around cell-state control. Reprogramming, rejuvenation, autophagy, and regenerative biologics attract the largest checks. Investors currently prefer interventions that directly change biological function over monitoring-only models.
- North America dominates both capital and deal flow. It holds 98.7% of disclosed capital and 87.5% of deals. Europe is scientifically present, but not yet a comparable scale-up financing environment.
- Stage labels can mislead in longevity biotech. Series A appears dominant by capital, but its median is only $20M. Retro’s $1B Series A makes the stage look more mature than it actually is.
- The market’s credibility hierarchy is clear. Regulatory milestones matter first, repeat high-quality investor participation second, disease-specific anchoring third, and broad longevity branding last.
BioSpace (BioAge Labs IPO), Shift Bioscience (Seed), HERVolution Therapeutics (Series A), Financial Times (Retro Biosciences), Business Wire (Loyal Series B), TechCrunch (NewLimit Series B), PR Newswire (OneSkin Series A), MarketScreener (NewLimit October 2025 financing), Generation Lab (Seed), Junevity (Seed expansion), Business Wire (Juvena Therapeutics Series B), PR Newswire (L-Nutra Series D), Business Wire (Loyal Series C), Life Biosciences (Series D), STAT (NewLimit Series C), Rapalogix Health (Series A)
Related blog posts
- A full list of funding deals in the longevity biotech market
- Which companies have raised the most funding in the longevity biotech market?
- Which companies are the most valued in the longevity biotech market?
